ARCT

Arcturus Therapeutics Holdings Inc. (ARCT) - 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended March 31, 2026. Arcturus Therapeutics is a clinical-stage messenger RNA (mRNA) medicines company focused on liver and respiratory rare disease therapeutics. Key assets include the KOSTAIVE vaccine (approved in Japan, EU, and UK) and therapeutic candidates for Cystic Fibrosis (LUNAR-CF/ARCT-032) and Ornithine Transcarbamylase deficiency (LUNAR-OTC/ARCT-810).

Key Financial Metrics

Note: Q1 2025 included $15.0 million in debt proceeds which were repaid/terminated by Q1 2026.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by 93% ($27.3 million) year-over-year. Collaboration revenue dropped 98% to $0.6 million, primarily due to reduced supply agreement revenue and deferred revenue amortization as the KOSTAIVE vaccine transitions to commercialization. Grant revenue fell 63% to $1.5 million, driven by lower BARDA reimbursements.
• Expense Reduction: Total operating expenses decreased 33% ($15.2 million). Research and Development (R&D) expenses fell 38% to $21.5 million, driven by lower manufacturing costs for LUNAR-COVID and BARDA programs, reduced clinical trial costs, and lower headcount. General and Administrative (G&A) expenses decreased 16% to $9.5 million.
• Increased Net Loss: Despite lower expenses, the net loss widened to $27.0 million from $14.1 million, primarily due to the significant drop in revenue and a decrease in interest income ($1.9 million vs. $2.8 million).
• Liquidity: Cash and cash equivalents decreased by $19.4 million during the quarter. The company terminated its Wells Fargo credit agreement in December 2025; no debt remains outstanding.

Guidance, Outlook, and Risks

• Partnership Dispute: Arcturus initiated arbitration against CSL Seqirus in May 2025 regarding a milestone payment tied to KOSTAIVE's EU marketing authorization. A hearing is scheduled for Q3 2026. CSL Seqirus reported a $430 million write-down related to this collaboration in February 2026.
• Legal Proceedings: The company is involved in litigation against AbbVie and Capstan Therapeutics regarding trade secret misappropriation. An amended complaint was filed in April 2026.
• Development Progress:
  • LUNAR-CF: Phase 2 trial enrollment for the initial three cohorts is complete; a fourth cohort began enrolling in March 2026.
  • LUNAR-OTC: Phase 2 enrollment continues. The FDA provided a path forward for a pivotal pediatric study following a Type C meeting in March 2026.
• Liquidity Outlook: Management believes current cash resources ($213.4 million total cash) are sufficient to fund operations for at least the next 12 months. However, the company expects to continue incurring losses and will require additional financing to support long-term plans.
• Risks: Key risks include the outcome of the CSL Seqirus arbitration, regulatory approval timelines, geopolitical disruptions (specifically in the Middle East), and the ability to secure future funding.

Investor Verification Checklist

• CSL Seqirus Arbitration: Verify the status and potential financial impact of the ongoing arbitration regarding the EU milestone payment.
• Revenue Recognition: Confirm the timing of future revenue recognition from the CSL collaboration and BARDA grants, given the significant Q1 decline.
• Cash Burn Rate: Assess the sustainability of the current cash position ($213.4 million) against the projected burn rate for Phase 2 trials and commercialization efforts.
• Lease Obligations: Review the remaining lease liabilities ($24.0 million) for the vacated San Diego office space, which remains an obligation through March 2027.
• Regulatory Pathways: Monitor FDA feedback on the LUNAR-OTC pediatric study design and the timeline for the End-of-Phase 2 meeting.